Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
**Rhox homeobox family member 1 pseudogene 2** (RHOXF1P2) is a processed pseudogene, meaning it is a noncoding sequence in the genome that arose from the Rhox homeobox family member 1 gene through retrotransposition events and has lost its protein-coding ability. RHOXF1P2 does not code for a functional protein, and there is no evidence it serves as a direct therapeutic target, receptor, enzyme, or transporter[5][1][3]. Pseudogenes like RHOXF1P2 may, however, play roles in gene regulation at the RNA level, such as acting as decoys for microRNAs or generating regulatory RNAs, thereby potentially influencing the expression of their parental genes or other genes involved in processes such as tumor suppression or oncogenesis[1]. No direct involvement of RHOXF1P2 in pathologies, nor any drug, biomarker, or safety concerns related to this pseudogene, have been reported in the scientific literature or gene databases[5]. **Note:** RHOXF1P2 is by definition *not* a conventional therapeutic target or receptor, and its function, if any, would be indirect or regulatory based on the emerging understanding of pseudogene biology[1][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Rhox homeobox family member 1 pseudogene 2 (RHOXF1P2).